Skip to main content

15-06-2020 | Haematology | Video

EHA25 | Isatuximab addition shows benefits in relapsed, refractory multiple myeloma

Philippe Moreau tells us why the phase 3 IKEMA trial supports the addition of the anti-CD38 agent isatuximab to carfilzomib plus dexamethasone as a potential new standard of care for relapsed or refractory multiple myeloma (5:52).

Funding for independent interviews at EHA25 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Image Credits